Treatment of basal cell carcinoma with intralesional interferon |
| |
| Authors: | H T Greenway R C Cornell D J Tanner E Peets G M Bordin C Nagi |
| |
| Affiliation: | 1. The Chinese University of Hong Kong, Hong Kong SAR;2. University of Amsterdam, The Netherlands;1. Department of Obstetrics and Gynecology, Warren Alpert Medical School, Brown University, Providence, RI (Drs Lewkowitz and Burrell);2. Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio, San Antonio, TX (Dr Ramsey);3. Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, UT (Dr Metz);4. Department of Obstetrics and Gynecology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI (Dr Rhoades) |
| |
| Abstract: | Eight patients with basal cell carcinomas were treated with recombinant alpha-2 interferon. Each patient had a biopsy-proved basal cell carcinoma of the nodular or superficial type that was injected intralesionally three times a week for 3 weeks (9 total injections) with 1.5 X 10(6) IU (0.15 ml) of alpha-2 interferon per injection (total dose, 13.5 X 10(6) IU). Excisional biopsy 2 months after completion of therapy revealed no evidence of basal cell carcinoma in any patient. Minimal side effects were observed. In these eight patients alpha-2 interferon was therefore an effective and safe modality of treatment. The encouraging results of this pilot study suggest that additional evaluation of interferon in the treatment of basal cell carcinoma is warranted. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
